Myomo, Inc.

NYSE American MYO

Myomo, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2024: USD 5.16 M

Myomo, Inc. Net Cash Used Provided By Financing Activities is USD 5.16 M for the Trailing 12 Months (TTM) ending September 30, 2024, a -48.84% change year over year. Net cash used/provided by financing activities are the total cash inflows and outflows related to activities that finance the company’s operations, including debt, equity, and dividends.
  • Myomo, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 10.09 M, a 111.11% change year over year.
  • Myomo, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 4.78 M, a -43.15% change year over year.
  • Myomo, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2021 was USD 8.41 M, a -57.01% change year over year.
  • Myomo, Inc. Net Cash Used Provided By Financing Activities for the Trailing 12 Months (TTM) ending September 30, 2020 was USD 19.56 M, a 256.00% change year over year.
Key data
Date Net Cash Used Provided By Financing Activities Dividends Paid Capital Expenditure Effect Of Forex Changes On Cash
Market news
Loading...
NYSE American: MYO

Myomo, Inc.

CEO Mr. Paul R. Gudonis
IPO Date June 12, 2017
Location United States
Headquarters 137 Portland Street
Employees 101
Sector Technology
Industries
Description

Myomo, Inc., a wearable medical robotics company, designs, develops, and produces myoelectric orthotics for people with neuromuscular disorders in the United States. The company offers MyoPro, a myoelectric-controlled upper limb brace or orthosis product used for supporting a patient's weak or paralyzed arm to enable and improve functional activities of daily living. Its products are designed to help improve function in adults and adolescents with neuromuscular conditions due to brachial plexus injury, stroke, traumatic brain injury, spinal cord injury, and other neurological disorders. The company sells its products to orthotics and prosthetics providers, the Veterans Health Administration, and rehabilitation hospitals, as well as through distributors. Myomo, Inc. was incorporated in 2004 and is headquartered in Boston, Massachusetts.

Similar companies

IRIX

IRIDEX Corporation

USD 1.61

-1.23%

SSKN

STRATA Skin Sciences, Inc.

USD 2.95

0.00%

SGHT

Sight Sciences, Inc.

USD 3.15

-2.78%

VVOS

Vivos Therapeutics, Inc.

USD 5.06

4.33%

NXL

Nexalin Technology, Inc.

USD 2.78

10.76%

BJDX

Bluejay Diagnostics, Inc.

USD 3.36

-7.95%

NUWE

Nuwellis, Inc.

USD 1.05

3.96%

HSCS

Heart Test Laboratories, Inc.

USD 3.26

1.24%

SINT

Sintx Technologies, Inc.

USD 3.21

-4.46%

RSLS

ReShape Lifesciences Inc.

USD 4.66

-6.80%

NVNO

enVVeno Medical Corporation

USD 3.14

-1.57%

StockViz Staff

January 15, 2025

Any question? Send us an email